24 Results for "

relapsed/refractory multiple myeloma

" in MedChemExpress (MCE) Product Catalog:
Products (24)

24 Results for "relapsed/refractory multiple myeloma" in MCE Product Catalog:

90
90 Publications Verification
Cat. No.: HY-10224
CAS No.: 404950-80-7
Purity:  99.37%
Synonyms: LBH589; NVP-LBH589
Target:  

HDAC Autophagy HIV Apoptosis

Research Areas:  

Cancer

Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities . Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells . Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma .
loading...
    loading...
90
90 Publications Verification
Cat. No.: HY-10224A
CAS No.: 960055-56-5
Purity:  98.67%
Synonyms: LBH589 lactate; NVP-LBH589 lactate
Target:  

HDAC HIV Autophagy Apoptosis

Research Areas:  

Infection Cancer

Panobinostat lactate is a potent and orally active non-selective HDAC inhibitor. Panobinostat lactate has antineoplastic activities. Panobinostat lactate effectively disrupts HIV latency. Panobinostat lactate induces cell apoptosis and autophagy. Panobinostat lactate can be used for the study of refractory or relapsed multiple myeloma .
loading...
    loading...
20
20 Cited Publications
Cat. No.: HY-101488
CAS No.: 1010100-07-8
Purity:  99.85%
CC-885, a cereblon (CRBN) modulator, acts as a molecular glue degrader targeting GSPT1 with a Kd of 350 nM. CC-885 binds to CRBN to alter the substrate specificity of the CRL4 E3 ligase, promoting the ubiquitination and proteasomal degradation of GSPT1, BNIP3L, PLK1, CDK4, IKZF1/3, GSPT2, WIZ, CHD7, GOLM1, CK1α and ETS1. CC-885 induces apoptosis, cell cycle arrest, transcriptional downregulation and antiproliferation in cancer cells. CC-885 is applicable to research related to relapsed/refractory acute myeloid leukemia, MYC-driven tumors, metastatic castration-resistant prostate cancer, multiple myeloma, hepatocellular carcinoma, glioblastoma, VHL-deficient clear cell renal cell carcinoma and non-small cell lung cancer .
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-136328
CAS No.: 2411759-92-5
Purity:  97.20%
Synonyms: SETD2-IN-1 TFA
Research Areas:  

Cancer

EZM0414 (SETD2-IN-1) TFA is the TFA salt form of EZM0414 (HY-144858). EZM0414 TFA is a potent, selective, orally active inhibitor of SETD2 (IC50=18 nM in SETD2 biochemical assay; IC50=34 nM in cellular assay). EZM0414 TFA can be used for the research of relapsed or refractory multiple myeloma and diffuse large B-cell lymphoma .
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-144858
CAS No.: 2411748-50-8
Purity:  99.11%
Research Areas:  

Cancer

EZM0414 is a potent, selective, orally bioavailable inhibitor of SETD2 (IC50=18 nM in SETD2 biochemical assay; IC50=34 nM in cellular assay). EZM0414 can be used for the research of relapsed or refractory multiple myeloma and diffuse large B-cell lymphoma .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P9980
CAS No.: 2061894-48-0
Synonyms: GSK2857914

Research Areas:  

Cancer

Belantamab (GSK2857916) is a humanized IgG1 anti-BCMA/TNFRSF17 monoclonal antibody. Belantamab is linked to MMAF (HY-15579) through a non-cleavable ADC linker to synthesize the antibody-active molecule conjugate (ADC) Belantamab mafodotin (HY-P3239). After binding to BCMA on the surface of tumor cells, Belantamab mafodotin enters the cell through receptor-mediated endocytosis. After entering the cell, Belantamab mafodotin releases MMAF, blocks cell division by inhibiting tubulin polymerization, arrests the cell cycle and induces cell apoptosis. Belantamab can be used for the study of multiple myeloma, especially relapsed/refractory multiple myeloma .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-154812
CAS No.: 2604513-16-6
Purity:  99.81%
Synonyms: KTX-1001
Research Areas:  

Cancer

Gintemetostat (KTX-1001) is an orally active, highly specific NSD2/MMSET histone methyltransferase inhibitor with human NSD2 IC50 values ranging 0.460-2.17 nM and NSD2 SET domain IC50 of 2.32 nM and Kd values ranging 6.3-70.4 nM .Gintemetostat reduces H3K36me2 levels, impairs multiple myeloma cell adhesion and colony formation, enhances cytotoxicity, boosts T-cell activation, and sensitizes resistant multiple myeloma cells to other agents .Gintemetostat can be used for the research of multiple myeloma and relapsed and refractory multiple myeloma .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99730
CAS No.: 2227490-52-8
Synonyms: TAK-079

Target:  

CD38 Apoptosis

Research Areas:  

Inflammation/Immunology Cancer

Mezagitamab (TAK-079) is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP) .
loading...
    loading...
Cat. No.: HY-P99909
CAS No.: 2408850-14-4
Synonyms: PF-06863135; RN-613

Target:  

TNF Receptor

Research Areas:  

Inflammation/Immunology

Elranatamab (PF-06863135) is an anti-CD3E/TNFRSF17 human IgG2κ monoclonal antibody . Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002).
loading...
    loading...
Cat. No.: HY-P991490

Target:  

CD38 CD3 TNF Receptor

Research Areas:  

Cancer

ISB2001 is a trispecific antibody targeting CD38, CD3 and BCMA. ISB2001 effectively counteracts tumor immune escape mechanisms caused by antigen downregulation, antigen loss, soluble factor competition and other factors. ISB2001 is applicable to relevant research on multiple myeloma and relapsed/refractory multiple myeloma .
loading...
    loading...
Cat. No.: HY-P9989
CAS No.: 2408319-25-3
Synonyms: REGN5458

Target:  

CD3 TNF Receptor

Research Areas:  

Cancer

Linvoseltamab (REGN5458) is a bispecific T-cell engager (BiTE) antibody that specifically binds to B cell maturation antigen (BCMA) and CD3 of T cells, thereby directing T cells to multiple myeloma (MM) cells expressing BCMA and activating T cells to kill tumor cells. Linvoseltamab can be used in research of relapsed/refractory multiple myeloma (RRMM) .
loading...
    loading...
Cat. No.: HY-P990980
CAS No.: 2919209-65-5
Synonyms: CND-106; EMB-06
Target:  

CD3

Research Areas:  

Inflammation/Immunology Cancer

Cizutamig (CND-106) is a bispecific T-cell engager targeting BCMA and CD3. Cizutamig exhibits immunostimulatory and anti-tumor activities. Cizutamig can be used in research related to relapsed or refractory multiple myeloma and systemic lupus erythematosus .
loading...
    loading...
Cat. No.: HY-150109
CAS No.: 2650188-32-0
Purity:  99.45%
Synonyms: Purinostat mesylate
Puzerinostat mesylate (Purinostat mesylate) is a highly selective class I/IIb histone deacetylase (HDAC) inhibitor, with IC50 values of 0.81 nM, 1.4 nM, 1.7 nM, 3.8 nM, 11.5 nM, and 1.1 nM against HDAC1, HDAC2, HDAC3, HDAC8, HDAC6, and HDAC10, respectively. Puzerinostat mesylate enhances glutamine metabolism by upregulating GLS1. Puzerinostat mesylate induces cell Apoptosis and downregulates the expression of BCR-ABL and c-MYC. Puzerinostat mesylate delays the progression of Ph + B-cell acute lymphoblastic leukemia and prolongs the survival of relevant mouse models. Puzerinostat mesylate regulates the immune microenvironment. Puzerinostat mesylate can be used in research related to chronic myeloid leukemia, Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia, relapsed/refractory multiple myeloma, relapsed/refractory lymphoma, diffuse large B-cell lymphoma, and double-expression lymphoma .
loading...
    loading...
Cat. No.: HY-P990095
CAS No.: 2408319-33-3
Synonyms: REGN5459

Target:  

CD3 TNF Receptor

Research Areas:  

Cancer

Vonsetamig (REGN5459) is a human bispecific antibody targeting BCMA and CD3. Vonsetamig triggers T-cell activation, induces plasma cell depletion, and triggers low-level cytokine release. Vonsetamig can be used for the research of relapsed/refractory multiple myeloma .
loading...
    loading...
Cat. No.: HY-P99454
CAS No.: 1826819-58-2
Synonyms: ABBV-838
Research Areas:  

Cancer

Azintuxizumab vedotin (ABBV-838) is an antibody–drug conjugate (ADC) targeting a unique epitope of CD2 subset 1, a cell-surface glycoprotein expressed on multiple myeloma cells .
loading...
    loading...
Cat. No.: HY-P991183

Target:  

CD28 CD38 CD3

Research Areas:  

Cancer

SAR-442257 is a trispecific T-cell engager and monoclonal antibody that binds to CD38, CD3 and CD28. SAR-442257 can target and bind to CD3 and CD28 on T cells, as well as CD38 expressed on tumor cells. SAR-442257 mediates T-cell activation, enhances T-cell activity, induces T-cell degranulation, and drives cytotoxicity against multiple myeloma cells. SAR-442257 functions via CD38 expression, and its in vitro activity correlates with CD38 expression on the surface of multiple myeloma cells. SAR-442257 can be used in studies related to multiple myeloma and relapsed/refractory multiple myeloma .
loading...
    loading...
Cat. No.: HY-10224R
CAS No.: 404950-80-7
Synonyms: LBH589 (Standard); NVP-LBH589 (Standard)
Research Areas:  

Infection Cancer

Panobinostat (Standard) (LBH589 (Standard)) is the analytical standard of Panobinostat (HY-10224). This product is intended for research and analytical applications. Panobinostat is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities . Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells . Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma .
loading...
    loading...
Cat. No.: HY-171754
Research Areas:  

Cancer

LM-305 is an anti-G protein-coupled receptor class 5 member D (GPRC5D) antibody-drug conjugate (ADC). LM-305 consists of Anti-GPRC5D Antibody (HY-P991197) and VcMMAE (HY-15575). LM-305 exhibits potent cytotoxicity against multiple myeloma cells (NCI-H929 and MM.1R) with IC50 values ranging from 0.1 to 0.3 nM. LM-305 can be used in the study of GPRC5D-related relapsed and refractory multiple myeloma (RRMM) .
loading...
    loading...
Cat. No.: HY-150109A
CAS No.: 1929583-17-4
Synonyms: Purinostat
Puzerinostat (Purinostat) is a highly selective class I/IIb histone deacetylase (HDAC) inhibitor, with IC50 values of 0.81 nM, 1.4 nM, 1.7 nM, 3.8 nM, 11.5 nM, and 1.1 nM against HDAC1, HDAC2, HDAC3, HDAC8, HDAC6, and HDAC10, respectively. Puzerinostat enhances glutamine metabolism by upregulating GLS1. Puzerinostat induces cell Apoptosis and downregulates the expression of BCR-ABL and c-MYC. Puzerinostat delays the progression of Ph + B-cell acute lymphoblastic leukemia and prolongs the survival of relevant mouse models. Puzerinostat regulates the immune microenvironment. Puzerinostat can be used in research related to chronic myeloid leukemia, Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia, relapsed/refractory multiple myeloma, relapsed/refractory lymphoma, diffuse large B-cell lymphoma, and double-expression lymphoma .
loading...
    loading...
Cat. No.: HY-P990939
CAS No.: 2851863-52-8
Synonyms: HPN 217
Target:  

CD3

Research Areas:  

Cancer

Podentamig (HPN 217) is a trispecific construct with three binding domains, including an anti-CD3 domain for T cell activation, an anti-BCMA domain for binding to plasma cells, and an anti-albumin domain for half-life extension. Podentamig is applicable to research related to relapsed/refractory multiple myeloma .
loading...
    loading...